AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Resistance to the new generation EGFR-TKI, Osimertinib, can emerge in patients with EGFR-mutated lung cancer. Here, the authors show that AXL, which is activated by osimertinib, can promote the emergence of tolerant lung cancer cell thus conferring resistance to osimertinib and propose the combinati...

Full description

Bibliographic Details
Main Authors: Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang, Keiko Tanimura, Yuta Adachi, Akihiro Nishiyama, Azusa Tanimoto, Shinji Takeuchi, Luiz H. Araujo, Mariana Boroni, Akihiro Yoshimura, Shinsuke Shiotsu, Isao Matsumoto, Satoshi Watanabe, Toshiaki Kikuchi, Satoru Miura, Hiroshi Tanaka, Takeshi Kitazaki, Hiroyuki Yamaguchi, Hiroshi Mukae, Junji Uchino, Hisanori Uehara, Koichi Takayama, Seiji Yano
Format: Article
Language:English
Published: Nature Portfolio 2019-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-08074-0

Internet

https://doi.org/10.1038/s41467-018-08074-0

Similar Items